The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
Sonali M. Smith, Heiko Schöder, Jeffrey L. Johnson, Sin Ho Jung, Nancy L. Bartlett, Bruce D. Cheson
Dive into the research topics of 'The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)'. Together they form a unique fingerprint.